Manatt Health senior advisor Ian Spatz spoke with WSJ Pro Venture Capital on President Trump’s recent decision to issue a series of executive orders aimed at lowering prescription drug costs, and the impact they might on investment in biotechnology. In particular, Spatz discussed one of the executive order’s impact on Medicare prices for medications under Part B, saying, “pegging Medicare Part B prices to international prices could have a significant impact on the profitability of current drugs and the development of new medicines that would be covered under this program.”